A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Trial Profile

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Renal cell carcinoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 01 Nov 2017 According to an Epizyme media release, data from the study will be presented during a plenary session at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2017.
    • 01 Nov 2017 According to an Epizyme media release, the company has added a separate cohort to enroll adults with chordoma, due to the high rate of enrollment of these patients in the other INI1-negative cohort.
    • 01 Nov 2017 According to an Epizyme media release, the patients in rhabdoid tumor cohort and other INI1-negative tumor cohort have both surpassed their futility assessment. The company is continuing to enroll and monitor patients in these arms and plans to present updated data from this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top